January 2023 | Blood Cancers Today

January 2023

This issue of Blood Cancers Today features a Get to Know with Jonathon Cohen, MD, MS, meeting news from the 2022 American Society of Hematology Annual Meeting, a feature on bispecific antibodies, and more.

Viewpoints

Guest Editor's Message

Taking the ‘Pulse’ of the New Year

Features

News

In the Literature

Survival Outcomes Poor After CAR-T Failure in Aggressive BCL

Lenalidomide Plus Rituximab Is a ‘Chemo-Free Alternative’ in Follicular Lymphoma

Meeting News

Phase III ALPINE Data Suggest Zanubrutinib Is Superior to Ibrutinib in CLL/SLL

Iberdomide Plus Dexamethasone Has ‘Encouraging’ Efficacy in R/R Myeloma

TRIANGLE Trial Results Support First-Line Ibrutinib Use in MCL

State of the Art

Present-Day BCL2 Inhibitor Therapy and Future Therapeutic Directions

Regulatory Actions

FDA Approves Brentuximab Vedotin for Pediatric High-Risk Hodgkin Lymphoma

BLA for Subcutaneous Epcoritamab in LBCL Granted FDA Priority Review

UK Regulator Grants ‘Innovation Passport’ Status to ALETA-001 for NHL, ALL

Zanubrutinib Gains European Commission Approval for CLL

BTK Inhibitor Approved in Singapore for Relapsed/Refractory MCL

Elranatamab Receives Breakthrough Therapy Designation

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer